UNSPSC 51421606: Clobetasone butyrate

This classification denotes a therapeutic glucocorticoid with the molecular formula C26H32ClFO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8U0H6XI6EO, chemically known as 21-chloro-9-fluoro-17-hydroxy-16-methylpregna-1,4-diene-3,11,20-trione 17-butyrate but more generally known as clobetasone butyrate, which bears US NIH Compound Identifier 71386. European Medicines Agency schedules Clobetasone butyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01347MIG.

UNSPSC 51421606 Clobetasone butyrate is a Commodity code for a specific topical corticosteroid pharmaceutical product, but the recent state and local procurement activity recorded under this code does not reflect purchases of the drug itself. Instead, Seminole County, Florida has used this code designation for an IFB seeking to procure naloxone and drug deactivation systems — products entirely outside the scope of the nominal commodity. The mismatch suggests either a classification error in the county's posting or a coding practice that does not align the UNSPSC designation to the goods actually being solicited. No recent state and local opportunities purchasing clobetasone butyrate under this code are present in the available data.

Seminole County's July 2026 IFB (IFB60459723LAS) called for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and a response deadline of July 26, 2023. The procurement required vendors to include all shipping and delivery costs in their bids, maintain drug-free workplace certification and E-Verify compliance, and comply with federal regulations including the Clean Air Act and Federal Water Pollution Control Act, potentially reflecting FEMA funding. Given the absence of relevant recent opportunities under the nominal code scope, professionals should verify whether suppliers in topical corticosteroids are targeting state and local pharmacy, dermatology, or healthcare operations through alternative code designations or direct RFP channels rather than expect continued activity under this code.